Iter-4360dd15-0074-transcript
第 74 轮执行轨迹
→ call search_memory({"limit":10,"query":"4360dd15 PMID 候选 摘要 年龄判据 主要终点 分类"}) → call list_recent({"n":8})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0059-transcript", "tags": "iteration transcript", "modified": "20260424195947000", "preview": "!! 第 59 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS PMID 10 条候选 研究类型 保留 排除 理由\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0073-reflection", "modified": "20260424202425000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424202425000", "tags": "pinned focus"}, {"title": "先做摘要级字段抽取", "modified": "20260424202425000", "tags": "lesson audit abstract-extraction classification"}, {"title": "Iter-4360dd15-0073-transcript", "modified": "20260424202419000", "tags": "iteration transcript"}, {"title": "Iter-4360dd15-0072-reflection", "modified": "20260424202124000", "tags": "iteration reflection"}, {"title": "先确认研究类型再谈终点", "modified": "20260424202124000", "tags": "lesson audit study-design endpoint"}, {"title": "Iter-4360dd15-0072-transcript", "modified": "20260424202113000", "tags": "iteration transcript"}, {"title": "Iter-4360dd15-0072-review-exclusion-first-rule", "modified": "20260424202103000", "tags": "4360dd15 knowledge method"}]}
→ call read_note({"title":"NEXT_FOCUS"})
→ call search_memory({"limit":12,"query":"4360dd15 candidate PMID abstract remaining"})
→ call list_by_tag({"limit":20,"tag":"4360dd15"})
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission `4360dd15` · Iter-0073）\n\n下一轮只做一件事：逐个读取剩余候选 PMID 的摘要，抽取研究类型、年龄判据和主要终点，并据此完成最终分类。"}
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0059-transcript", "tags": "iteration transcript", "modified": "20260424195947000", "preview": "!! 第 59 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 14 候选 PMID 研究类型 误纳入 original clinical study extension follow-up ancillary\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【【tool:list_by_tag】
{"ok": true, "items": [{"title": "Iter-4360dd15-0072-review-exclusion-first-rule", "modified": "20260424202103000"}, {"title": "Iter-4360dd15-0071-minimal-audit-rules", "modified": "20260424201843000"}, {"title": "Iter-4360dd15-0069-standardized-audit-table-two-trials", "modified": "20260424201621000"}, {"title": "Iter-4360dd15-0068-abstract-endpoint-extraction", "modified": "20260424201407000"}, {"title": "Iter-4360dd15-0067-abstract-endpoints-aging-criteria", "modified": "20260424201141000"}, {"title": "Iter-4360dd15-0066-TierA-abstracts-and-endpoints-for-aging-criteria", "modified": "20260424200925000"}, {"title": "Iter-4360dd15-0065-minimal-relevance-decision-rules-for-retained-mtor-trials", "modified": "20260424200748000"}, {"title": "Iter-4360dd15-0064-relevance-tiering-10-pmids", "modified": "20260424200602000"}, {"title": "Iter-4360dd15-0063-10-pmid-audit-table", "modified": "20260424200432000"}, {"title": "Iter-4360dd15-0062-pubmed-title-verification-10-pmids", "modified": "20260424200328000"}, {"title": "Iter-4360dd15-0061-candidate-audit-10-remaining-pmids", "modified": "20260424200221000"}, {"title": "PMID 38310895 is a review, not a primary trial", "modified": "20260424200109000"}, {"title": "PMID 35040506 longitudinal analysis is embedded in primary trial", "modified": "20260424195939000"}, {"title": "Iter-4360dd15-0058-longevity-evidence-proximity-tagging", "modified": "20260424195827000"}, {"title": "Iter-4360dd15-0057-study-design-taxonomy-for-retained-trials
→ call search_memory({"limit":10,"query":"4360dd15 remaining candidate PMID list audit table"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0059-transcript", "tags": "iteration transcript", "modified": "20260424195947000", "preview": "!! 第 59 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 PMID 38310895 reference chain Crossref 75 references human trial rapamycin everolimus sirolimus\"}) → call list_recent({\"n\":8}) → call list_tools({}) 【tool:search_m → call read_note({"title":"Iter-4360dd15-0061-candidate-audit-10-remaining-pmids"})
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0061-candidate-audit-10-remaining-pmids", "tags": "4360dd15 knowledge fact classification clinical-trials", "text": "!! 第 61 轮：剩余 10 条候选 PMID 的研究类型审计完成\n\n本轮把上一轮留下的“剩余 10 条候选”逐条核对，并与已知的 4 条二次/延伸研究合并成 14 条完整清单。\n\n!! 结论\n- 保留 10 条：均可视为原始临床研究\n- 排除 4 条：标题明确指向 ancillary / follow-up / extension / postextension\n\n!! 保留 PMID\n- 33977284\n- 22367193\n- 29408453\n- 22115710\n- 35040506\n- 25525171\n- 24618547\n- 18037627\n- 27613521\n- 29992557\n\n!! 排除 PMID\n- 29806044\n- 31781682\n- 30564495\n- 34693520\n\n!! 最小可复现判定规则\n1. 标题若显式包含 `ancillary` / `follow-up` / `extension` / `postextension`，则排除为非原始研究。\n2. 标题若包含 `randomized` / `placebo-controlled` / `phase` / `pilot` / `proof-of-concept` / `single-arm`，不要自动排除；它们仍可能是原始临床研究。\n3. `longitudinal analysis` 若嵌在主试验题名中，只作为主试验附带分析，不单独构成排除理由。\n\n!! 复现备注\n- 先用记忆回忆上一轮留下的候选上下文\n- 再逐条对照题名进行结构化分类\n- 本轮已把“剩余 10 条候选”从噪声中清理为可审计的保留/排除结果"}
→ call search_memory({"limit":8,"query":"4360dd15 35040506 abstract age endpoint"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0010-transcript", "tags": "iteration transcript", "modified": "20260424175830000", "preview": "!! 第 10 轮执行轨迹
→ cal"}, {"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹 →"}, {"title": "Iter-4360dd15-0037-transcript", "tags": "iteration transcript", "modified": "20260424191347000", "preview": "!! 第 37 轮执行轨迹 → call search_memory({"limit":8,"query":"35040506"})
→ call pubmed_search({"limit":3,"query":"35040506"})
→ call pubmed_search({"limit":3,"query":"29992557"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0059-transcript", "tags": "iteration transcript", "modified": "20260424195947000", "preview": "!! 第 59 轮执行轨迹
→ call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS 剩余 10 条候选 PMID 研究类型 保留 排除 理由 extension follow-up secondary analysis\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0055-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424195425000\", \"previe"}, {"title": "Iter-4360dd15-0065-transcript", "tags": "iteration transcript", "modified": "20260424200755000", "preview": "!! 第 65 轮执行轨迹 "}, {"title": "Iter-4360dd15-0055-transcript", "tags": "iteration transcript", "modified": "20260424195425000", "preview": "!! 第 55 轮执行轨迹 【tool:pubmed_search】
{"ok": true, "query": "35040506", "results": [{"pmid": "35040506", "title": "mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.", "source": "Mov Disord", "pubdate": "2022 Apr", "authors": ["Palma JA", "Martinez J", "Millar Vernetti P", "Ma T", "Perez MA", "Zhong J", "Qian Y", "Dutta S"], "url": "https://pubmed.ncbi.nlm.nih.gov/35040506/"}]}
【tool:pubmed_search】
{"ok": true, "query": "29992557", "results": [{"pmid": "29992557", "title": "Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.", "source": "Int J Cancer", "pubdate": "2019 Feb 15", "authors": ["Tesch H", "Stoetzer O", "Decker T", "Kurbacher CM", "Marmé F", "Schneeweiss A", "Mundhenke C", "Distelrath A"], "url": "https://pubmed.ncbi.nlm.nih.gov/29992557/"}]}
→ call web_fetch({"max_chars":6000,"url":"https://pubmed.ncbi.nlm.nih.gov/35040506/"})
→ call web_fetch({"max_chars":6000,"url":"https://pubmed.ncbi.nlm.nih.gov/29992557/"})
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/35040506/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/29992557/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call web_search({"limit":5,"query":"35040506 abstract PMID 35040506"})
→ call web_search({"limit":5,"query":"29992557 abstract PMID 29992557"})
【tool:web_search】
{"ok": true, "query": "35040506 abstract PMID 35040506", "results": [{"title": "mTOR Inhibition with Sirolimus in Multiple System Atrophy: A ... - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/35040506/?dopt=Abstract", "snippet": "Abstract Background: Multiple system atrophy (MSA) is a fatal neurodegenerative disease characterized by the aggregation of α-synuclein in glia and neurons. Sirolimus (rapamycin) is an mTOR inhibitor that promotes α-synuclein autophagy and reduces its associated neurotoxicity in preclinical models."}, {"title": "A Futility Trial of Sirolimus in Multiple System Atrophy", "url": "https://clinicaltrials.gov/study/NCT03589976?tab=researcher", "snippet": "Interim analysis showed early evidence of futility of sirolimus. Trial stopped per DSMB recommendation."}, {"title": "mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized ...", "url": "https://europepmc.org/article/MED/35040506", "snippet": "Abstract Background: Multiple system atrophy (MSA) is a rare neurodegenerative disease characterized by the aggregation of α-synuclein in glia and neurons. Sirolimus (rapamycin) is an mTOR inhibitor that promotes α-synuclein autophagy and reduces its associated neurotoxicity in preclinical models."}, {"title": "(PDF) mTOR Inhibition with Sirolimus in Multiple System Atrophy: A ...", "url": "https://www.researchgate.net/publication/357912770_mTOR_Inhibition_with_Sirolimus_in_Multiple_System_Atrophy_A_Randomized_Double-Blind_Placebo-Controlled_Fu
【tool:web_search】
{"ok": true, "query": "29992557 abstract PMID 29992557", "results": [{"title": "Efficacy and safety of everolimus plus exemestane in postmenopausal ...", "url": "https://pubmed.ncbi.nlm.nih.gov/29992557/", "snippet": "Abstract In BOLERO-2, adding everolimus to exemestane resulted in a twofold increase in median progression-free survival (PFS) vs exemestane in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) after progression on a non-steroidal aromatase inhibitor ..."}, {"title": "Efficacy and safety of the combination of metformin, everolimus and ...", "url": "https://europepmc.org/article/MED/30610588", "snippet": "Similar Articles To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation."}, {"title": "Google Scholar", "url": "https://scholar.google.com/", "snippet": "Google Scholar provides a simple way to broadly search for scholarly literature. Search across a wide variety of disciplines and sources: articles, theses, books, abstracts and court opinions."}, {"title": "Efficacy and safety of everolimus plus exemestane in postmenopausal ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6587781/", "snippet": "Keywords: estrogen receptor‐positive, HER2‐negative, advanced breast cancer, everolimus, exemestane Short abstract What's new? Current treatment guidelines for HR+, HER2- advanced bre
→ call web_search({"limit":6,"query":"35040506 age inclusion criteria abstract clinical trial adult"})
【tool:web_search】
{"ok": true, "query": "35040506 age inclusion criteria abstract clinical trial adult", "results": [{"title": "PDF Age-Friendly Research: promoting inclusion of older adults in clinical ...", "url": "https://www.cambridge.org/core/services/aop-cambridge-core/content/view/FCF29960C3BAC40BD2FD1A6C9CC38C02/S2059866123006271a.pdf/div-class-title-age-friendly-research-promoting-inclusion-of-older-adults-in-clinical-and-translational-research-div.pdf", "snippet": "Yet older adult participation in clinical and translational research has been limited [2 -4]. Studies often underrepresent older adults due to arbitrary age limits for study inclusion , not enrolling sufficient older adults , or including healthier older adults than the general population [5]."}, {"title": "Inclusion of Older Adults in Cancer Clinical Trials | FDA", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inclusion-older-adults-cancer-clinical-trials", "snippet": "This guidance provides recommendations regarding the inclusion of older adult patients in clinical trials of drugs."}, {"title": "PDF Inclusion of Older Adults in Cancer Clinical Trials", "url": "https://www.hhs.gov/guidance/sites/default/files/hhs-guidance-documents/FDA/2020-831_InclusionofOlderAdultsinCancerClinicalTrials_final.pdf", "snippet": "For the purpose of this guidance, older adults are those 65 years of age and older. Specifically, this guidance includes recommendations for including an adequate representation
→ call web_search({"limit":8,"query":"\"35040506\" age inclusion criteria MSA trial 48 weeks abstract"})
→ call web_search({"limit":8,"query":"\"29992557\" age postmenopausal women phase IIIB 4EVER trial abstract endpoint"})
【tool:web_search】
{"ok": true, "query": "\"35040506\" age inclusion criteria MSA trial 48 weeks abstract", "results": [{"title": "NYUHSL Faculty Bibliography", "url": "https://library.med.nyu.edu/api/publications/?person=kaufmh06&sort=display_rank&in-biosketch=true&offset=40", "snippet": "CONCLUSIONS:Sirolimus for 48 weeks was futile to slow the progression of MSA and had no effect on biomarkers compared to placebo. One-year change in blood NfL and whole brain atrophy are promising biomarkers of disease progression for future clinical trials . © 2022 International Parkinson and Movement Disorder Society. PMID: 35040506"}, {"title": "NYUHSL Faculty Bibliography", "url": "https://library.med.nyu.edu/api/publications/?person=millap02&sort=display_rank&in-biosketch=yes", "snippet": "CONCLUSIONS:Sirolimus for 48 weeks was futile to slow the progression of MSA and had no effect on biomarkers compared to placebo. One-year change in blood NfL and whole brain atrophy are promising biomarkers of disease progression for future clinical trials . © 2022 International Parkinson and Movement Disorder Society. PMID: 35040506"}]}
【tool:web_search】
{"ok": true, "query": "\"29992557\" age postmenopausal women phase IIIB 4EVER trial abstract endpoint", "results": [{"title": "CSLA, CSM : l'association de l'évérolimus et de l'exémestane fonctionne ...", "url": "https://www.univadis.fr/index.php/viewarticle/csla-csm-lassociation-de-leverolimus-et-de-lexemestane-fonctionne-bien-dans-lessai-allemand4ever", "snippet": "Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial . Int J Cancer. 2018 Jul 11 [Epub ahead of print]. doi: 10.1002/ijc.31738. PMID: 29992557"}, {"title": "LABC, MBC: Everolimus plus Exemestan schneidet in deutscher 4EVER ...", "url": "https://www.univadis.de/index.php/viewarticle/labc-mbceverolimusplusexemestan-schneidet-in-deutscher-4ever-studie-gut-ab", "snippet": "Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial . Int J Cancer. 2018 Jul 11 [Epub ahead of print]. doi: 10.1002/ijc.31738. PMID: 29992557"}]}
→ call web_search({"limit":5,"query":"Europe PMC 35040506 abstract age criteria primary endpoint"})
→ call web_search({"limit":5,"query":"Europe PMC 29992557 abstract endpoint postmenopausal women age criteria"})
【tool:web_search】
{"ok": true, "query": "Europe PMC 35040506 abstract age criteria primary endpoint", "results": [{"title": "Europe PMC", "url": "https://europepmc.org/", "snippet": "Comprehensive search Search life sciences literature from trusted sources around the globe, all in one search, accessible by anyone anywhere, for free. Learn more About Europe PMC ."}, {"title": "PMC Home", "url": "https://pmc.ncbi.nlm.nih.gov/", "snippet": "PMC is a free full-text archive of biomedical and life sciences journal literature at the U.S. National Institutes of Health's National Library of Medicine (NIH/NLM)."}, {"title": "Daratumumab monotherapy versus active monitoring in patients with high ...", "url": "https://ashpublications.org/blood/article/146/Supplement 1/372/553332/Daratumumab-monotherapy-versus-active-monitoring", "snippet": "Primary endpoint was progression-free survival (PFS) assessed by independent review committee, defined as progression to active MM (based on IMWG SLiM-CRAB diagnostic criteria ) or death. Secondary endpoints included time to first-line (1L) MM tx and OS."}, {"title": "Diagnostic Criteria and Endpoint | Springer Nature Link", "url": "https://link.springer.com/chapter/10.1007/978-3-031-60843-8_5", "snippet": "Abstract Diagnosis testing has become a crucial component of evidence-based patient care. In rare and pediatric disease, because of the limited understanding on the natural history of the diseases and inherently heterogeneous in the diseases, delay in correctly
【tool:web_search】
{"ok": true, "query": "Europe PMC 29992557 abstract endpoint postmenopausal women age criteria", "results": [{"title": "European guidance for the diagnosis and management of osteoporosis in ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7026233/", "snippet": "Abstract Summary Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk from fractures due to osteoporosis."}, {"title": "PDF European guidance for the diagnosis and management of ... - Esceo", "url": "https://www.esceo.org/sites/esceo/files/pdf/European_guidance_for_the_diagnosis_and_management_of_osteoporos_is_in_postmenopausal_women_OI_2012_KANIS_et_al.pdf", "snippet": "Abstract Summary Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis."}, {"title": "PDF European guidance for the diagnosis and management of ... - Springer", "url": "https://link.springer.com/content/pdf/10.1007/s00198-008-0560-z.pdf", "snippet": "Abstract Summary Gu
```